ARDELYX Aktie

 

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW),......

Ardelyx's Chief Commercial Officer, Eric Foster, is named as an individual defendant in a securities class action alleging he assured investors the Company's patient-access strategy was working while payer prior authorization and step edit requirements were allegedly restricting IBSRELA......

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ardelyx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Ardelyx between January 13, 2025 and August 6, 2026 and would like to......

Ardelyx's chief executive, two successive chief financial officers, and its chief commercial officer are each named as individual defendants in a securities class action alleging they controlled public statements projecting $1.75 billion in combined peak sales for XPHOZAH and IBSRELA......

NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ardelyx, Inc. (NASDAQ: ARDX) between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"), of the important November 16, 2026 lead plaintiff......

WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 11:30 a.m. GMT / 6:30 a.m. ET....

LOS ANGELES, Nov. 9, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the......

NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW),......

NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ardelyx, Inc. (NASDAQ: ARDX) between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"), of the important November 16, 2026 lead plaintiff......

Important Notice Regarding Alleged Payer Access and Reimbursement Misrepresentations: the lawsuit contends Ardelyx pointed investors toward $1.75 billion in combined peak sales while payer utilization-management barriers were allegedly restricting patient starts for IBSRELA and XPHOZAH.......

NEW YORK, Nov. 5, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the......

A securities class action chronicles how Ardelyx allegedly reaffirmed billion-dollar sales targets for IBSRELA and XPHOZAH across 19 months while payer prior authorization and step edit barriers were allegedly slowing new-patient starts. NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Levi &......

Doubling the field reimbursement team targets prior authorization friction, a hurdle that can stall prescriptions even after demand is established....

Patient awareness push and IBSRELA sales growth both gained momentum this quarter....

LOS ANGELES, Nov. 4, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Ardelyx (ARDX) delivered earnings and revenue surprises of +100.00% and +2.55%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?...

While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....

Q3 2026 total product revenue of $125.5 million, reflecting 19% growth year-over-year...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...